To evaluate the therapeutic efficacy and utilization of targeting CD39 in the preclinical model of NSCLC, we established PDOs and found that CD39 knockout in PDOs caused more than 60% increases in Teff subset ratios and about 50% reduction in Treg proportion. The gene discussed is ENTPD1; the disease is non-small cell lung carcinoma.